Effective dose of escitalopram in moderate versus severe DSM-IV major depression

Pharmacopsychiatry

Volumn 39, Issue 4, 2006, Pages 128-134

  Bech, Per ^a   Andersen, H F ^b   Wade, A ^c  

^a FREDERIKSBORG GENERAL HOSPITAL   (Denmark)

^b H LUNDBECK A S   (Denmark)

^c CPS Clinical Research Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HYPOTHESIS; MAJOR DEPRESSION; MALE; MEDICAL RECORD; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 33746882420     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-946702     Document Type: Article

References (36)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fourth edition (DSM-IV). Washington DC: American Psychiatric Association, 1994
2. Bagby RM, Ryder AG, Schuiler DR, Marshall MB. The Hamilton Depression Rating Scale: Has the gold standard become a lead weight? Am J Psychiatry 2004; 161: 2163-2177
3. Barbui C, Hotopf M. Amitryptiline v the rest: still the leading antidepressant after 40 years of randomised clinical trials. Br J Psychiatry 2001; 178: 129-144
4. Bech P, Cialdella P, Haugh M, Birkett MA, Hours A, Boissel JP, Tollefson GD. A meta-analysis of randomised controlled trials of fluoxetine versus placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry 2000; 176: 421-428
5. Bech P, Tanghøj P, Cialdella P, Friis AH, Pedersen AG. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Psychopharmacol 2004; 7: 283-290
6. Bech P. Pharmacological treatment of depressive disorders: A review. In: Maj M, Sartorius N. (eds). Depressive disorders in psychiatry Chichester: Wiley, second edition, 2002
7. Bulpitt CJ. Medical statistics: meta-analysis. Lancet 1988; 2: 93-94
8. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331-336
9. Chen F, Larsen MB, Sánchez C, Wiborg O. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. European Neuropsychopharmacology 2005; 15: 193-198
10. Cohen J. Statistical power analysis for the behavioural sciences. Mahwah, NJ: Lawrence Erlbaum, 1988
11. Colonna L, Reines EH, Andersen HF. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive patients with major depressive disorder. Curr Med Res Opin 2005; 21: 1659-1668
12. Demyttenaere K, Mesters P, Boulanger B, Dewe W, Delsemme MH, Gregoire J, Van Ganse E. Adherence to treatment regimen in depressed patients treated with amitriptyline or fluoxetine. J Affect Disord 2001; 65: 243-252
13. Fahre LF, Abuzzahab FS, Amin M, Claghorn JL, Mendels J, Petrie WM et al. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 1995; 38: 592-602
14. Faries D, Herrera J, Rayamajhi J, DeBrota D, Demitrack M, Potter WZ. The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res 2000; 34: 3-10
15. Gorman J, Korotzer A, Su G. Efficacy Comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 2002; 7 (4 Suppl 1): 40-44
16. Gram LF. Fluoxetine. N Eng J Med 1994; 331: 1354-1361
17. Kragh-Sorensen P, Hansen CE, Baastrup PC, Hvidberg EF. Self-inhibiting action of nortryptilin's antidepressive effect at high plasma levels. Psychopharmacologia 1976; 45: 306-312
18. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18: 211-217
19. Licht RW, Qvitzau S, Allerup P, Been P. Validation of the Bech-Rafaelsen Melancholia Scale and the Hamilton Depression Scale in patients with major depression: is the total score a valid measure of illnes severity? Acta Psychiatr Scand 2005; 111: 144-199
20. Mittmann N, Mitter S, Borden EK, Herrmann N, Naranjo CA, Shear NH. Montgomery-Asberg severity gradations. Am J Psychiatry 1997; 154: 1320-1321
21. Moncrieff J, Kirsch I. Efficacy of antidepressants in adults. BMJ 2005; 331: 155-157
22. Moncrieff J. Are antidepressants overrated? A review of methodological problems in antidepressant trials. J Nerv Ment Dis 2001; 189: 288-295
23. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389
24. Müller MJ, Szegedi A, Wetzel H, Benkert O. Moderate and severe depression. Gradations for the Montgomery-Asberg Depression Rating Scale. J Affect Disord 2000; 60: 137-140
25. Ninan PT, Ventura D, Wang J. Escitalopram is effective and well tolerated in the treatment of severe depression. Data presented at the 156th Annual Meeting of the American Psychiatric Association, 17-22 May 2003, San Francisco, CA. Further details available at http://www.forestclinicaltrials.com/CTR/ CTRController/CTRViewPdf?_file_id = scsr/SCSR_SCT-MD-26_final.pdf
26. Olsen RL, Mortensen EL, Bech P. Prevalence of major depression and stress indicators in the Danish general population. Acta Psychiatr Scand 2004; 109: 96-103
27. O'Sullivan RL, Fava M, Augustin C, Baer L, Rosenbaum JF. Sensitivity of the six-item Hamilton Depression Rating Scale. Acta Psychiatr Scand 1997; 95: 379-384
28. Peto R. Why do we need systematic overviews of randomised trials. Stat Med 1987; 6: 233-244
29. Preskorn SH. Recent dose-effect studies regarding antidepressants. In: Balant LP, Benitez J, Dahl SG. (eds). Clinical pharmacology in psychiatry: finding the right dose of psychotropic drugs Brussels: European Commission, 1998: pp 45-61
30. Reisby N, Gram LF, Bech P, Sihm F, Krautwald O, Elley J, Ortmann J, Christiansen J. Clomipramine: Plasma levels and clinical effects. Communications in: Psychopharmacology 1979; 3: 341-351
31. Rifkin A. SSRI optimal dose remains at issue. J Clin Psychiatry 1997; 58: 87-88
32. Sánchez C, Bøgesø KP, Ebert B, Reines EH, Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology 2004; 174: 163-176
33. Schmid JE, Koch G, La Vange LM. An overview of statistical issues and methods of meta-analyses. J Biopharm Stat 1991; 1: 103-120
34. Stein DJ, Andersen HF, Goodman WK. Escitalopram for the treatment of GAD: Efficacy across different subgroups and outcomes. Ann Clin Psychiatry 2005; 17: 71-75
35. Wade A, Lemming OM, Hedegaard KB. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17: 95-102
36. World Health Organisation. International Classification of Diseases, tenth revision (ICD-10). Diagnostic criteria for research. Geneva: World Organisation; Geneva, 1993